Andrei I Veresiu1, Cosmina I Bondor2, Bogdan Florea3, Etta J Vinik4, Aaron I Vinik5, Norina A Gâvan6. 1. Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca, Department of Diabetes, Nutrition and Metabolic Diseases, 4-6 Clinicilor Street, Cluj-Napoca, Romania. 2. Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca, Department of Medical Informatics and Biostatistics, 6 Pasteur Street, Cluj-Napoca, Romania. Electronic address: cosmina_ioana@yahoo.com. 3. Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca, 8 Victor Babes Street, IMOGEN Research Center, Cluj-Napoca, Romania. 4. Eastern Virginia Medical School, Strelitz Diabetes Center, 855 West Brambleton Avenue, Norfolk, VA, USA. 5. Eastern Virginia Medical School, Neuroendocrine Unit, 855 West Brambleton Avenue, Norfolk, VA, USA. 6. Wörwag Pharma GmbH&Co.KG, Romanian Representative Office, Society of Diabetic Neuropathy, 11 Fagului Street, Cluj-Napoca, Romania.
Abstract
AIMS: The objective of this cross-sectional survey was to capture undiagnosed neuropathy in Romanian patients with self-reported diabetes using Norfolk QoL-DN as a screening tool and to assess its impact on quality of life (QoL). METHODS: 25,000 Romanian-translated, validated Norfolk QoL-DN questionnaires were distributed between June and December 2012. 21,261 patients who self-reported diabetes and answered questions related to neuropathy, ulceration, gangrene and amputation were included in the analysis. RESULTS: 52% of diabetic patients (n = 6615) who answered "no" to the question "Do you have neuropathy?" had total QoL scores above the cut-off, suggesting the presence of diabetic neuropathy. 13,854 (65.2%) patients answered "yes" to the question "Do you have neuropathy?" and 3,150 (14.8%) reported at least one episode of ulceration, gangrene or amputation. Total QoL score was 3-fold higher (worse) for patients who answered "yes" to the question "Do you have neuropathy?" than for those who answered "no" (38.39 vs. 13.71; p < 0.001) and 1.4-fold worse for patients who reported ulceration, gangrene or amputation than for those who did not report any of these (50.38 vs. 34.87; p < 0.001). CONCLUSIONS: We found a high prevalence of undisclosed diabetic neuropathy in this population and showed that neuropathy severity has an increasing impact on total QoL and its domains.
AIMS: The objective of this cross-sectional survey was to capture undiagnosed neuropathy in Romanian patients with self-reported diabetes using Norfolk QoL-DN as a screening tool and to assess its impact on quality of life (QoL). METHODS: 25,000 Romanian-translated, validated Norfolk QoL-DN questionnaires were distributed between June and December 2012. 21,261 patients who self-reported diabetes and answered questions related to neuropathy, ulceration, gangrene and amputation were included in the analysis. RESULTS: 52% of diabeticpatients (n = 6615) who answered "no" to the question "Do you have neuropathy?" had total QoL scores above the cut-off, suggesting the presence of diabetic neuropathy. 13,854 (65.2%) patients answered "yes" to the question "Do you have neuropathy?" and 3,150 (14.8%) reported at least one episode of ulceration, gangrene or amputation. Total QoL score was 3-fold higher (worse) for patients who answered "yes" to the question "Do you have neuropathy?" than for those who answered "no" (38.39 vs. 13.71; p < 0.001) and 1.4-fold worse for patients who reported ulceration, gangrene or amputation than for those who did not report any of these (50.38 vs. 34.87; p < 0.001). CONCLUSIONS: We found a high prevalence of undisclosed diabetic neuropathy in this population and showed that neuropathy severity has an increasing impact on total QoL and its domains.
Authors: Brian C Callaghan; Rong Xia; Mousumi Banerjee; Nathalie de Rekeneire; Tamara B Harris; Anne B Newman; Suzanne Satterfield; Ann V Schwartz; Aaron I Vinik; Eva L Feldman; Elsa S Strotmeyer Journal: Diabetes Care Date: 2016-03-10 Impact factor: 19.112
Authors: Kara R Mizokami-Stout; Zoey Li; Nicole C Foster; Viral Shah; Grazia Aleppo; Janet B McGill; Richard Pratley; Elena Toschi; Lynn Ang; Rodica Pop-Busui Journal: Diabetes Care Date: 2020-02-06 Impact factor: 17.152
Authors: Cosmina I Bondor; Ioan A Veresiu; Bogdan Florea; Etta J Vinik; Aaron I Vinik; Norina A Gavan Journal: J Diabetes Res Date: 2016-02-25 Impact factor: 4.011
Authors: Norina A Gavan; Ioan A Veresiu; Etta J Vinik; Aaron I Vinik; Bogdan Florea; Cosmina I Bondor Journal: J Diabetes Res Date: 2016-11-29 Impact factor: 4.011